85333-43-3

Basic information

• Product Name: 8-CHLORO-2-METHYLIMIDAZO[1,2-A]PYRAZINE
• Synonyms: 8-CHLORO-2-METHYLIMIDAZO[1,2-A]PYRAZINE;8-chloro-2-MethyliMidazo[1;8-Chloro-2-MethyliMidazol[1,2-a]pyrazine
• CAS NO: 85333-43-3
• Molecular Formula: C₇H₆ClN₃
• Molecular Weight: 167.6
• Mol File: 85333-43-3.mol

Chemical Properties

• Appearance: /
• Density: 1.43 g/cm³
• Refractive Index: 1.681
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 2.51±0.30(Predicted)
• CAS DataBase Reference: 8-CHLORO-2-METHYLIMIDAZO[1,2-A]PYRAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 8-CHLORO-2-METHYLIMIDAZO[1,2-A]PYRAZINE(85333-43-3)
• EPA Substance Registry System: 8-CHLORO-2-METHYLIMIDAZO[1,2-A]PYRAZINE(85333-43-3)

Safety Data

• Hazardous Substances Data: 85333-43-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
8-CHLORO-2-METHYLIMIDAZO[1,2-A]PYRAZINE is used as a research compound for studying DNA damage and mutations due to its mutagenic and genotoxic properties. This helps in understanding the mechanisms of action and potential applications in drug development.
Used in Agricultural Industry:
In the agricultural industry, 8-CHLORO-2-METHYLIMIDAZO[1,2-A]PYRAZINE is used as a chemical intermediate in the synthesis of various biologically active compounds, which can be utilized for pest control and crop protection.
Used in Food Industry:
8-CHLORO-2-METHYLIMIDAZO[1,2-A]PYRAZINE is used as a flavoring agent in food products, contributing to the enhancement of taste and aroma profiles.
Used in Chemical Research:
8-CHLORO-2-METHYLIMIDAZO[1,2-A]PYRAZINE is used as a chemical intermediate in the synthesis of various organic compounds, facilitating the development of new materials and pharmaceuticals.

InChI:InChI=1/C7H6ClN3/c1-5-4-11-3-2-9-6(8)7(11)10-5/h2-4H,1H3

Upstream product

• 6863-73-6 3-chloropyrazin-2-amine 
• 126-38-5 1-bromo-2,2-dimethoxypropane 
• 78-95-5 chloroacetone 

Downstream Products

• 1334166-66-3 3-[1-(2-chlorobenzyl)-1H-pyrazol-4-yl]-2-methyl-8-morpholin-4-ylimidazo[1,2-a]pyrazine 
• 1436383-95-7 2-fluoro-4-[2-methyl-8-[(3-methylsulfonylphenyl)methylamino]imidazo[1,2-a]pyrazin-3-yl]phenol 
• 1124321-01-2 4-[2-methyl-8-[(3-methylsulfonylphenyl)methylamino]imidazo[1,2-a]pyrazin-3-yl]phenol 
• 1124320-61-1 4-[[[3-(4-hydroxyphenyl)-2-methyl-imidazo[1,2-a]pyrazin-8-yl]amino]methyl]benzenesulfonamide 
• 1436383-97-9 3-bromo-2-methyl-N-[(3-methylsulfonylphenyl)methyl]imidazo[1,2-a]pyrazin-8-amine 
• 1124321-37-4 4-[(3-bromo-2-methyl-imidazo[1,2-a]pyrazin-8-ylamino)-methyl]-benzenesulphonamide 
• 1124321-36-3 3-bromo-8-chloro-2-methyl-imidazo[1,2-a]pyrazine 
• 110206-70-7 3-amino-2-methyl-8-(2-phenylethyl)imidazo<1,2-a>pyrazine 

Relevant articles and documents

SUBSTITUTED TETRAHYDROQUINOLINONE COMPOUNDS AS ROR GAMMA MODULATORS

The present invention provides substituted tetrahydroquinolinone and related compounds of formula (I), which are therapeutically useful as modulators of Retinoic acid receptor-related orphan receptors (RORs), more particularly as RORγ modulators. These co

INHIBITORS OF PHOSPHODIESTERASE 10 ENZYME

The present invention relates to novel imidazo[1,2-b]pyridazine and imidazo[1,2-a]-pyrazine derivatives which are inhibitors of the phosphodiesterase 10 enzyme (PDE10) and which may be useful for the treatment or prevention of neurological, psychiatric and metabolic disorders in which the PDE10 enzyme is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, to the use of such compounds or pharmaceutical compositions for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases.

Discovery of a potent, selective, and orally active phosphodiesterase 10A inhibitor for the potential treatment of schizophrenia

We report the discovery of a series of imidazo[1,2-a]pyrazine derivatives as novel inhibitors of phosphodiesterase 10A (PDE10A). In a high-throughput screening campaign we identified the imidazopyrazine derivative 1, a PDE10A inhibitor with limited select

INHIBITORS OF PHOSPHODIESTERASE 10 ENZYME

The present invention relates to novel imidazo[1,2-b]pyridazine and imidazo[1,2-a]-pyrazine derivatives which are inhibitors of the phosphodiesterase 10 enzyme (PDE10) and which may be useful for the treatment or prevention of neurological, psychiatric and metabolic disorders in which the PDE10 enzyme is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, to the use of such compounds or pharmaceutical compositions for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases.

Identification of a series of compounds with potent antiviral activity for the treatment of enterovirus infections

Rhinovirus (genus enterovirus) infections are responsible for many of the severe exacerbations of asthma and chronic obstructive pulmonary disease. Other members of the genus can cause life-threatening acute neurological infections. There is currently no antiviral drug approved for the treatment of such infections. We have identified a series of potent, broad-spectrum antiviral compounds that inhibit the replication of the human rhinovirus, Coxsackie virus, poliovirus, and enterovirus-71. The mechanism of action of the compounds has been established as inhibition of a lipid kinase, PI4KIIIβ. Inhibition of hepatitis C replication in a replicon assay correlated with enterovirus inhibition.

IMIDAZO[1,2-a]PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES

The present invention relates to novel imidazo[1,2-a]pyrazine derivatives which are inhibitors of the phosphodiesterase 10 enzyme (PDE10) and which are useful for the treatment or prevention of neurological, psychiatric and metabolic disorders in which the PDE10 enzyme is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, to the use of such compounds or pharmaceutical compositions for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases.

IMIDAZO [1, 2 -A] PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES

The present invention relates to novel imidazo[1,2-a]pyrazine derivatives which are inhibitors of the phosphodiesterase 10 enzyme (PDE10) and which are useful for the treatment or prevention of neurological, psychiatric and metabolic disorders in which the PDE10 enzyme is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, to the use of such compounds or pharmaceutical compositions for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases.

IMIDAZOPYRAZINE COMPOUNDS

Novel imidazopyrazine compounds are disclosed that have a formula represented by the following: Formula (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a viral infection, in particular a HCV, HRV, Sb and/or CVB in a patient in need thereof.

IMIDAZO COMPOUNDS AND USES THEREOF

N-substituted imidazopyrazinone compounds such as N-alkylated/aralkylated 7H-imidazo[1,2-a]pyrazin-8-one compounds and related analogs are disclosed. Pharmaceutical compositions and kits containing the N-substituted imidazopyrazinone compounds, as well as therapeutic uses thereof, including treatment of arrhythmia, are also disclosed.

Antiulcer Agents. 2. Gastric Antisecretory, Cytoprotective, and Metabolic Properties of Substituted Imidazolpyridines and Analogues

The search for a successor to 3-(cyanomethyl)-2-methyl-8-(phenylmethoxy)imidazopyridine, Sch 28080 (27), a compound that exhibits gastric antisecretory and cytoprotective properties and has undergone clinical evaluation as an antiulcer agent, has culminated in the identification of four related compounds that exhibit pharmacologic profiles similar to that of 27.In three of these potential successors an amino group functions as a surrogate for the 3-cyanomethyl substituent of the prototype.The present work concerns, in addition to an evaluation of the structure-activity relationships of a series of analogues of 27, preliminary studies of the pharmacodynamics and metabolism of 27, performed with the aid of cyano carbon labeled versions of the drug (13C labeled; 28; 14C labeled, 29).These studies have shown that 27 is well-absorbed and extensively metabolized and that the major metabolite of 27 is the thiocyanate anion.A similar study performed on 3-amino-2-methyl-8-(phenylmethoxy)imidazopyridine, labeled at the 3-position with carbon-13 (41) or carbon-14 (42), revealed that this compound, which has an antisecretory/cytoprotective profile comparable to that of 27, is also metabolized to thiocyanate anion, although this must occur via a different mechanism.The chemistry section includes a discussion of the potential sites of protonation of the pharmacologically similar 3-amino analogue 40 and the structurally related imidazopyrazine 67.Predictions based on charge density and protonation product stabilities are presented.That N1 is the site of protonation in these analogues has been definitively demonstrated by X-ray crystal structure analysis, which alsounequivocally established the assigned imidazopyrazine ring structure.